Claris Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Lever Bio develops immunotherapy drug candidates in immuno-oncology, partnering with top researchers and academic institutions to translate discoveries into cancer immunotherapies.
BiotechDeep TechHealthtechMedical Devices
Pietro Puglisi(Chief Executive Officer)in
Co-investorsExor VenturesItalian Angels for GrowthClub degli InvestitoriOra Global
Haptena Therapeutics is a biotech company developing next-generation immunotherapies for oncogene-driven, genetically defined cancers, starting with KRAS-driven tumors.
BiotechHealthtech
Chiara Ambrogio(Co-founder)Roberto Chiarle(Co-founder)
IAMA Therapeutics develops small-molecule drugs for autism, epilepsies, and other central nervous system disorders, focusing on inhibiting cation-chloride cotransporters to correct atypical brain activity.
BiotechDeep Tech
Co-investorsCDP Venture CapitalIndaco Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.






